Premium
Dupilumab for pediatric prurigo nodularis: A case report
Author(s) -
Fachler Tahel,
Maria Faitataziadou Sofia,
MolhoPessach Vered
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14464
Subject(s) - prurigo nodularis , dupilumab , medicine , dermatology , prurigo , atopic dermatitis , refractory (planetary science) , rescue therapy , girl , dermatologic agents , surgery , psychology , developmental psychology , physics , astrobiology , microbiology and biotechnology , biology , antibiotics
Herein we report on a 9‐year‐old girl with recalcitrant prurigo nodularis unresponsive to multiple standard treatments. She was started on dupilumab therapy with rapid improvement in pruritus within 2 weeks and near complete regression of lesions at 3 months. Dupilumab should be considered as an off‐label treatment for refractory prurigo nodularis in children.